Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging Technologies and New Therapeutic Candidates17 Sep 2010 • by Natalie Aster
LONDON – MarketPublishers Ltd announces that new report “Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates" elaborated by Business Insights is available in its catalogue.
This market report’s highlight falls upon the monoclonal antibodies segment – the report provides explanation and description of the product itself and more than 80 proprietary technologies currently in use around the world. It incorporates more than 30 diagrams illustrating the science and technology of monoclonal antibodies, both as they appear in nature and in the myriad new forms now being assessed in preclinical trials. Moreover predictions on new-age kinds of drug that will enter clinical trials in the next 1-4 years and the respective market in the future 10-year period are provided.
Title: Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates
Published: March, 2010
Report Sample Abstract
Various companies busy in the monoclonal antibodies industry are performing different preclinical trials in association with related agencies, universities and licensors.
Agensys Inc (Santa Monica, CA, US) used XenoMouse® technology to identify AGS-16M18, a fully human IgG1 monoclonal antibody that binds AGS-16 on the surface of kidney cancer cells: In vivo efficacy data were presented at the 99th annual AACR meeting in San Diego, April 2008, validating AGS-16 as a therapeutic target for kidney and liver cancers. Agensys’ website has not been updated since the company was acquired by Astellas Pharma in December 2007, but Agensys is still using its original name in presentations and press releases, and now describes itself as “an affiliate of Astellas”.
Alopexx Pharmaceuticals LLC (Cambridge, MA, US) has completed at least some of its preclinical trials of F598, a fully human monoclonal antibody developed by Dr Gerald Pier at Harvard’s Brigham and Women’s Hospital, which binds to a conserved bacterial surface polysaccharide known as poly-N-acetyl glucosamine (PNAG). In December 2009, Alopexx announced a collaboration with sanofi-aventis (Paris, France) for a “first-in-class human monoclonal antibody” against PNAG, currently in preclinical development, with potential utility in preventing/treating S. aureus, S. epidermidis, E. coli, Y. pestis (plague) and other serious infections.
To order the report or ask for free sample pages contact email@example.com
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970